Northwest Biotherapeutics is a biotechnology company that develops personalised immune therapies for cancer. The company develops its products based on DCVax technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Its lead product, DCVax-L, is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer and if successful could help many people. The data has not yet been released for this phase.
Last month it was announced that the company was granted a HTA license required to work with human tissue for medical products at their UK site. A regulatory inspection of the facility has also been conducted by the UK Medicines and Health Products Regulatory Authority.